The intensity of immune activation is linked to the level of CCR5 expression in human immunodeficiency virus type 1-infected persons

Immunology

Volumn 137, Issue 1, 2012, Pages 89-97

  Portales, Pierre ^a   Psomas, Katerina Christina ^a,b   Tuaillon, Edouard ^a   Mura, Thibault ^a   Vendrell, Jean Pierre ^a   Eliaou, Jean François ^a   Reynes, Jacques ^a   Corbeau, Pierre ^b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Activation marker; CD38; Cell surface density; HIV co receptor; T cell activation

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ADULT; AGED; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IMMUNITY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; RECEPTORS, CCR5; RECEPTORS, DEATH DOMAIN; VIRAL LOAD;

EID: 84864754562     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03609.x     Document Type: Article

References (41)

1. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and pronostic value. Clin Exp Immunol 1992; 90:376-82.
2. Coetzee LM, Tay SS, Lawrie D, Janossy G, Glencross DK. From research tool to routine test: CD38 monitoring in HIV patients. Cytometry B Clin Cytom 2009; 76:375-84.
3. +, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable. Clin Exp Immunol 2000; 122:72-8.
4. + T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol 2005; 175:6117-22.
5. + T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194:29-37.
6. Kuller LH, Tracy R, Belloso W et al. Inflammatory and coagulation biomarkers in patients with HIV infection. PLoS Med 2008; 5:e203.
7. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-67.
8. Balagopal A, Philp FH, Astemborski J et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-33.
9. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
10. Wu Y, Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 2009; 5:e1000520.
11. Ahr B, Robert-Hebmann V, Devaux C, Biard-Piechaczyk M. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004; 23:12.
12. Taub DD, Ortaldo JR, Turcovski-Correlates SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996; 59:81-6.
13. Taub DD, Turcovski-Correlates SM, Key ML, Longo DL, Murphy WJ. Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro.. J Immunol 1996; 156:2095-103.
14. Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997; 158:4129-36.
15. Appay V, Dunbar PR, Cerundolo V, McMichael A, Czaplewski L, Rowland-Jones SL. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol 2000; 12:1173-82.
16. Lillard JJW, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. J Immunol 2001; 166:162-9.
17. Makino Y, Cook DN, Smithies O et al. Impaired T cell function in RANTES-deficient mice. Clin Immunol 2002; 102:302-9.
18. Camargo JF, Quinones MP, Mummidi S et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 2009; 182:171-82.
19. Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, Curiel TJ. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000; 165:4388-96.
20. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, Viola A. CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci USA 2008; 105:10101-6.
21. Molon B, Gri G, Bettella M, Gomez-Mouton C, Lanzavecchia A, Martinez-A C, Viola A. T cell costimulation by chemokine receptors. Nat Immunol 2005; 6:465-71.
22. + T cell-dendritic cell interaction. Nature 2006; 440:890-5.
23. + T cell response to respiratory virus infections. Immunity 2008; 29:101-13.
24. Zamilpa R, Kanakia R, Cigarroa JI et al. CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011; 300:H1418-26.
25. Zhang H, Yang H, Ma W, He S. Induction of IL-13 production and upregulated expression of protease activated receptor-1 by RANTES in a mast cell line. Cytokine 2011; 523:231-8.
26. Chritmann BS, Moran JM, McGraw JA, Buller RM, Cornbett JA. CCR5 regulates inflammatory gene expression in response to encephalomyocarditis virus infection. Am J Pathol 2011; 179:2941-51.
27. + T cell surface CCR5 density as a determining factor of viral load in HIV-1-infected individuals. J Infect Dis 2000; 181:927-32.
28. Vincent T, Portales P, Baillat V et al. T-cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists. J Acquir Immune Defic Syndr 2005; 38:305-9.
29. Lin Y-L, Mettling C, Portalès P, Réant B, Robert-Hebmann V, Reynes J, Clot J, Corbeau P. The efficiency of R5 infection is determined by CD4 T cell surface CCR5 density through Gai-protein signaling. AIDS 2006; 20:1369-77.
30. Desmetz C, Lin Y-L, Mettling C, Portalès P, Rabesandratana H, Clot J, Corbeau P. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 2006; 119:551-61.
31. + T-cell count. Cytometry B Clin Cytom 2009; 76B:249-60.
32. + T cells is a typical feature of natural SIV hosts. Blood 2007; 109:1069-76.
33. Ahuja SK, Kulkarni H, Catano G et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008; 14:413-20.
34. + cell response despite sustained virologic suppression: ATCG 5256. 17th Conference on Retroviruses and Opportunistic Infections 2010; Abstract 285.
35. Gutiérrez C, Diaz L, Hernandez-Novoa B et al. Effect of the intensification with a CCR5 antagonist on the decay of the HIV-1 latent reservoir and residual viremia. 17th Conference on Retroviruses and Opportunistic Infections 2010; Abstract 284.
36. + T cell recovery during suppressive ART. 18th Conference on Retroviruses and Opportunistiv Infections, 27 February-2 March 2011, Boston 2011.
37. + cell count. 49th ICAAC, San Francisco, CA, USA, September 12-15, Poster H-921 2009; Poster H-921.
38. Lalezari J, Yadavalli GK, Para M, Richmond G, DeJesus E, Brown SJ et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197:721-7.
39. Saag M, Goodrich J, Fätkenheuer G et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199:1638-47.
40. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 count changes: a meta-analysis of recent clinical trials in treatment-experienced subjects. 15th Conference on Retroviruses and Opportunistic Infections, Boston 2008 Feb 2-6 2008; Abstract 800.
41. + T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328-37.